LucidQuest’s Post

Thoughts on this? >> Merck asks DC federal court for IRA decision 'as soon as practicable' >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #productmarketing #healthcare

Have you checked out WIT's latest Hatch-Waxman report yet? In this latest edition, we cover all things related to Senior Judge Richard Andrews and offer detailed insights into his caseload. Contact Team WIT if you have any questions or want to learn more about how we gathered our data! #hatchwaxman #anda #districtcourt

The Inflation Reduction Act (IRA) has introduced significant changes to the pharmaceutical landscape. Navigating these changes is no easy task – our team has been at the forefront, supporting clients with tailored strategies to navigate through all stages of the product life cycle. Learn more about the key implications of the IRA and how we can support your organization: https://lnkd.in/eDgYrta5 Alice Valder Curran, Ken Choe, Melissa Bianchi, Philip Katz, Cullen Taylor, Kathleen Peterson, Samantha D. Marshall, and Mahmud Brifkani. #Pharmaceuticals #biotech #drugpricing #InflationReductionAct

Although the 2024 election results are now clear, the impact on the #biopharmaceutical industry remains uncertain. As Trump and the Republican party move away from a pro-big business agenda and towards a vigorous populist view of economic policy, any wins on such issues as reforming the #IRA negotiation rules or reigning in the #340B drug discount program will come at a price that may create winners and losers among companies. Ian Spatz provides key observations on these topics and other implications of the election on the #pharmaceutical and #biotech industries: https://lnkd.in/eUZ74B7M

Thoughts on this? >> Merck KGaA avoids prosecution after cooperating with DOJ to uncover China export scheme >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #productmarketing #healthcare #pharmaceutical

📢 What changes at the FDA under the Trump administration? ➡️ With the recent appointment of Mehmet Oz as head of the CMS and Martin Makary as Director or the FDA, the biopharmaceutical industry is wondering what the consequences might be for regulatory approval processes. Certain therapeutic areas could see their development affected by these new guidelines. 🔍 Find out which therapeutic areas are affected and why this is attracting so much attention (Data from Stifel Bank 2024 report). To contact our team for your financial needs in Life Sciences (see in the comments) 👇 #lifesciences #pharma #health Gery Lefebvre

Important and key insights from leading industry experts.

The Inflation Reduction Act’s price negotiation provision is poised to potentially reshape the pharma landscape. So how are pharmaceutical companies, especially those currently in price negotiations with the federal government, talking about the potential impacts to their investors and the public? Check out my report, the first in a series analyzing how pharmaceutical companies are communicating about the IRA. Please reach out if you have any questions or would like to learn more. And special thanks to my colleagues Simona Kormanikova, Camilla White, Juliet Stern and Natasha Otton for their help in putting this together. #pharma #healthcare #healthpolicy

Dentons Global Advisors observations on the Inflation Reduction Act (IRA) and how pharma companies and investors are talking about it on earnings calls. Thanks to DGA Partner John Capodanno and DGA's Complex Communications Advisory team!

As #drugmakers look to optimize #manufacturing processes to meet demand for new and complex drugs, as well as combat record high drug shortages, some experts are pointing to a production method that could help tackle these dueling challenges: continuous manufacturing. The manufacturing method, which relies on continuously inputting materials into the production process, has been used in other industries like food for decades. Yet the #pharmaceutical industry hasn’t quite caught up yet. Some in the sector, however, say that could change as more companies see the method’s merits.